1. The Lilly MDR-TB Partnership Creating a sustainable strategy for combating a global public health pandemic Increasing Corporate Engagement on Tuberculosis Metropolitan Auditorium, Cape Town, 23.02.2010

2. 2 Since 2003, Lilly has lead a comprehensive approach to fighting MDR-TB through Awareness and Prevention Treatment, Training and Surveillance Research Transferring Technology Community Support and Patient Advocacy Reaching patients throughout the world 360° Approach: Partnership Overview

3. 3 International Organizations and NGOs –International Federation of Red Cross & Red Crescent Societies –World Health Organization –Foundation for Professional Development –Centers for Disease Control –World Economic Forum –Global Business Coalition –UNICEF –USAID Government Departments –Department of Health –Department of Public Service and Administration Healthcare Provider Networks –International Hospital Federation –International Council of Nurses - DENOSA –World Medical Association - SAMA Manufacturing Partners –Aspen Pharmacare (South Africa) –Hisun (China) –Shasun (India) –SIA/Biocom (Russia) The Partners

4. 4 World Economic Forum/GBC  Develop a Global Awareness Toolkit for Tuberculosis/MDR-TB in the workplace and disseminate through WEF/GBC member companies  Provide educational material targeting employees and in- plant healthcare staff  Pilot tested in India and adapt for other high-burden countries with large business communities  Conducted 3 workshops in South Africa in 2009 reaching over 60 participants from 33 companies Workplace Toolkit

5. 5 Transferring of Technology  Share Lilly’s specific and general manufacturing knowledge  Create self-sustaining centers of manufacturing excellence capable of providing additional products and employment  Support reliable generic producers to ensure expanded multi-source availability of the two drugs  Offer manufacturing firms in MDR-TB “hot spots” the technology to produce capreomycin and cycloserine  Give training in GMPs and Good Business Practices  Provide 10 full-time Lilly staff on-site over 4 years for technical assistance/training  Facilities in China and India receive technology to produce capreomycin and cycloserine API’s respectively, and South Africa and Russia produce both products

6. 6 Technology successfully transferred to “hot spot” producers

7. 7 THANK YOU!!!

8. 8 Thank You! Dr Osborn Mahanjana Corporate Affairs Director Lilly MDR-TB Partnership mahanjanaos@lilly.com South Africa www.lilly.com www.lillymdr-tb.com